Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870158 | 1.00 | CTSK (0.43) | CTSKCTSBALDH1A1CTSSCTSL | |
| SCHEMBL7300652 | 0.86 | ALDH1A1 (0.40) | CTSKCTSBALDH1A1 | |
| SCHEMBL8711997 | 0.85 | PPARG (0.44) | ALDH1A1 | |
| SCHEMBL8711993 | 0.85 | PPARG (0.44) | ALDH1A1 | |
| SCHEMBL8055631 | 0.84 | CA1 (0.44) | CTSKALDH1A1 | |
| SCHEMBL16115639 | 0.84 | ALDH1A1 (0.43) | CTSBALDH1A1CTSSCTSL | |
| SCHEMBL18256487 | 0.83 | ALDH1A1 (0.47) | CTSKALDH1A1CTSSCTSL | |
| SCHEMBL3525448 | 0.83 | ALDH1A1 (0.47) | CTSKALDH1A1CTSSCTSL | |
| SCHEMBL20276639 | 0.83 | ALDH1A1 (0.47) | CTSKALDH1A1CTSSCTSL | |
| SCHEMBL7344531 | 0.83 | BLM (0.41) | ALDH1A1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-1998007742-A1 | SULFONAMIDES | ZENECA LIMITED (GB) | 1998-02-26 | — | — | WO | disclosed |
| US-5380921-A | Enzyme inhibitors for endothelin converting enzyme for cardiovascular disorders and atherosclerosis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-01-10 | — | — | US | disclosed |
| EP-0623625-A1 | Aminophosphonic acid derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | CTSK 541/4885CTSB 438/4885ALDH1A1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.